Market Research Reports, Inc. has announced the addition of “Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape” research report to their offering. More information visit- http://mrr.cm/ZkC

1. Category : Pharma & Healthcare
All logos and Images mentioned on this slide belong to their respective owners.
www.MarketResearchReports.com

2. Introduction to Report
 Launch Date: January 31, 2014
 Number of Pages: 120
 Geography Coverage: Global
 Available Format: PDF
Price For Single User License: USD 3,500
Price For Site License: USD 7,000
Price For Global User License: USD 10,500
Delivery Time: Within 24 Hours (During Working Days)
www.MarketResearchReports.com

3. About the Report
Due to a large untreated patient pool and the recent
approval of new treatments, the hepatitis C market will
more than treble from $5.7 billion in 2012 to $18.6 billion
by 2019, at an impressive Compound Annual Growth Rate
(CAGR) of 18.5%.
The company’s new report* states that the hepatitis C
market will receive this major boost with the 2013
approval of Sovaldi, which has the potential to transform
the treatment algorithm for hepatitis C. Due to the clinical
potential of the drug, Sovaldi will be very
expensive, reaching a cost of $86,000 annually and setting
a high price benchmark for future drugs.
www.MarketResearchReports.com

4. Research Findings
Analyst of this report says: “Sovaldi boasts excellent
tolerability and a Sustained Virologic Response rate
approaching 100%, without specificity to any genotype 1.
In genotypes 2 and 3, Sovaldi is administered with
ribavirin alone, alleviating the need for Pegasys or
Pegintron and therefore reducing the rate of adverse
events associated with these two therapies. As a result,
many patients who have previously deferred treatment
are expected to re-enter the market and use Sovaldi.”
Additional drugs, such as Olysio, which was also
approved in 2013, and daclatasvir are anticipated to
compete with Sovaldi, although they are not proven to be
as effective and can only be used in genotype 1 infections.
www.MarketResearchReports.com

5. Research Findings Continues…
According to publisher, Sovaldi-ledipasvir and ABT-450
triple therapy will further advance the hepatitis C market
and displace older drugs from 2015 onwards. This is due
to the fact that these therapies can be used without
peginterferon and have demonstrated 100% efficacy in
genotype 1, with strong tolerability and low dosing.
“The late-stage pipeline for hepatitis C is exceptionally
promising, and we expect new products to completely
transform the clinical and commercial landscape during
the forecast period,” Analyst concludes.
www.MarketResearchReports.com

6. Scope
A brief introduction to hepatitis C, including the disease’s
pathogenesis, risk factors and diagnosis, and detailed
analyses of disease epidemiology and treatment
algorithms.
In-depth analysis of the major antiviral drugs used in the
treatment of hepatitis C, including analyses of their safety,
efficacy, treatment patterns and strengths/weaknesses.
Includes a heat map that compares marketed drugs in
terms of safety and efficacy.
A comprehensive review of the pipeline for hepatitis C
therapies, including individual analysis of a number of
late-stage pipeline drugs that are likely to enter the
market during the forecast period. The pipeline is
analyzed by phase distribution, molecule type and
molecular target.
www.MarketResearchReports.com

7. Scope Continues…
In-depth clinical trial enrolment, trial duration and
program failure rate analyses for each molecule type and
mechanism of action. Additionally, clinical trial endpoints
and certain selection criteria are analyzed in great depth.
This section also includes an additional heat map
regarding pipeline products, and a direct cross-analysis
against currently marketed products.
Multi-scenario forecast data of the market to
2019, which takes into account the effects of the
introduction of new drugs, the expiry of key patents on
current drugs and the changes in disease epidemiology
across
the
key
developed
markets:
US, Canada, Japan, Germany, UK, France, Italy and Spain.
Discussion of the drivers and barriers for market growth.
Analysis of licensing and co-development deals occurring
in the hepatitis C market.
www.MarketResearchReports.com

8. Report Coverage
1.
2.
3.
4.
5.
6.
7.
8.
Table of Contents
Introduction
Marketed Products
Developmental Pipeline
Market Forecast to 2019
Drivers and Barriers
Licensing and Co-development deals
Appendix
For more details regarding Report coverage see the last slide
All logos and Images mentioned on this slide belong to their respective owners.
www.MarketResearchReports.com

9. Custom Research:
 Are you an industry professional, entrepreneur,
venture capitalist, investors and organization, then let
us know your specific research requirements. Our goal
is to cater to your requirements be it for a custom
market research project, syndicated research report on
a specific market or industry sector, newsletter creation,
case study development or anything else related to
marketing research.
For Any Customization Related query Visit IdeaCenter @
http://www.marketresearchreports.com/idea-center
www.MarketResearchReports.com

10. How To Buy This Report?
Visit following URL to see Table of Content and
purchase this publication:
http://www.marketresearchreports.com/gbiresearch/hepatitis-c-therapeutics-major-developedmarkets-2019-outstanding-recent-approvals-and
About Market Research Reports, Inc.
Market Research Reports provides a customized set
of reports from reputed Publishers, built on the
intelligence available within organizations and
leverages on our motto of “Intelligence Redefined”.
Contact : Amitava Sen
Email : info@marketresearchreports.com
Phone: +1 302-703-7787 (USA) +91-8762746600 (India)
www.MarketResearchReports.com